Pharmacokinetics of low molecular weight heparins in animal models

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 3, 1999, Pages 51-55

  Fareed, Jawed ^a   Kaiding, F U ^a   Hui Yang, L I ^a   Hoppensteadt, Debraa ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anti xa activity; Low molecular weight heparins; Pharmacokinetics

Indexed keywords

ARDEPARIN; CERTOPARIN; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; HUMAN; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; DISEASE MODELS, ANIMAL; FACTOR XA; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LIPOPROTEINS;

EID: 0032746094     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Piazolo L, Harenberg J, Maisch R, Hüttner FG, Heene DL. Comparison of the pharmacodynamic and pharmacokinelic profiles of two low molecular mass heparins in rats. Semin Thromb Hemost 1997;23:109-117
2. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low molecular weight heparin preparations the same? Semin Thromb Hemost 1996;22(Suppl 1):77-91
3. Fareed J, Walenga JM, Kumar A, Rock A. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemost 1985:11:155-175
4. Fareed J, Hoppensteadt D, Huan X, Racanelli A. Comparative study on the in vitro and in vivo activities of seven low molecular weight heparins. Hacmostasis 1989;18 (Suppl 3):3-15
5. Hoppenstaedt D, Jeske W, Fareed J. Pharmacological profile of reviparin-sodium. Blood Coag Fibrinol 1993;4(Suppl 1):S11-S16
6. Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins: Are they different? Can J Cardiol 199S;14(Suppl E):28E-34E
7. Fareed J, Kumar A, Rock A, Walenga JM, Davis P. A primate model (Macaco mulatto) to study the pharmacokinetics of heparin and its fractions. Semin Thromb Hemost I985;ll: 138-154
8. Brieger D, Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997;77:317-322
9. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 1992;3:439-449
10. Petersen CC, Björn SE, Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 1992;67:537-541
11. Lindahl AK, Abildgaard U, Larsen ML, et al. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin-induced coagulation. Thromb Res 1991; 14(Suppl):39-4t8
12. Abildgaard U. Relative role of tissue factor pathway inhibitor and antithrombin in the control of thrombogenesis. Blood Coag Fibrinolysis 1995;6:S45-S49
13. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag Fibrinolysis 1995; 6:S7-13
14. Hoppensteadt DA, Jeske W, Fareed J, Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediation of the anti-thrombotic actions of heparin and low molecular weight heparin. Blood Coag Fibrinolysis 1995;6:S57-64
15. Bognacki J, Hammelburger J. Functional and immunologie methods for the measurement of human tissue factor pathway inhibitor. Blood Coag Fibrinolysis 1995;6:S65-72
16. Fareed J, Jeske W, Eschenfelder V, et al. Preclinical studies on a low molecular weight heparin. Thromb Res 1996;81:Sl-27
17. Hansen JB, Sandset PM. Differential effects of low molecular weight heparin and UFH on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): A possible mechanism for difference in therapeutic efficacy. Thromb Res 1998;91:177-81
18. Hansen JB, Sandset PM, Huseby KR, et al. Differential effect of UFH and low molecular weight heparin on intravascular tissue factor pathway inhibitor: Evidence for a difference in antithrombotic action. Br J Haematol 1998;101:638-646
19. Barrowcliffe TW. Low molecular weight heparin(s). Br J Haematol 1995;90:l-7